Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SOLV
SOLV logo

SOLV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
71.230
Open
70.090
VWAP
70.36
Vol
980.12K
Mkt Cap
12.15B
Low
69.820
Amount
68.97M
EV/EBITDA(TTM)
13.66
Total Shares
173.41M
EV
16.38B
EV/OCF(TTM)
44.39
P/S(TTM)
1.48
Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.
Show More

Events Timeline

(ET)
2026-02-26
16:20:00
Sees 2026 Organic Revenue Growth of 2%-3%
select
2026-02-26
16:20:00
Solventum Q4 Revenue $2B, Exceeds Expectations
select

News

PRnewswire
9.5
04-14PRnewswire
Solventum to Release Q1 2026 Financial Results on May 5
  • Earnings Release Schedule: Solventum is set to release its Q1 2026 financial results on May 5, 2026, after U.S. market close, which is expected to provide investors with critical financial data and operational performance insights.
  • Webcast Discussion: Following the earnings release, Solventum management will host a webcast at 3:30 p.m. CDT on May 5 to discuss the financial results and other forward-looking information, aiming to enhance investor understanding of the company's future direction.
  • Dial-in Information: Investors can participate in the webcast using the U.S. dial-in number +1 (800) 715-9871 or the international dial-in number +1 (646) 307-1963, ensuring broad investor engagement and interaction.
  • Replay and Material Access: A replay of the webcast, along with the earnings press release, presentation slides, and supplemental financial disclosures, will be available in the Investor Relations section of Solventum's website, allowing investors to access relevant information at their convenience.
Yahoo Finance
9.5
04-12Yahoo Finance
Solvac Reports 2025 Earnings: Mixed Signals
  • Revenue vs. Net Income: Solvac reported €0.003769 million in revenue for 2025, a 22% decline from the previous year, yet net income rose to €125.31 million, indicating improved profitability despite lower sales, reflecting effective cost control and operational efficiency.
  • Stock Price Volatility: While Solvac's share price increased by 10.61% over the past month, its one-year total shareholder return declined by 13.66%, suggesting market concerns about its long-term performance, prompting investors to carefully assess the sustainability of this short-term rebound.
  • Valuation Analysis: With a P/E ratio of 12.5x, significantly lower than its peers at 37.5x and the European chemicals industry average of 17.6x, Solvac appears undervalued, especially given its 19.7% earnings growth over the past year, indicating potential investment opportunities.
  • Discounted Cash Flow Model: The SWS DCF model estimates Solvac's fair value at €91.61 per share, compared to its current trading price of €73, reflecting a 20.3% discount, leading investors to consider whether future risks justify this valuation gap.
NASDAQ.COM
4.5
03-24NASDAQ.COM
US Stocks Decline Amid Ongoing Iran Conflict
  • Market Performance: On Tuesday, the S&P 500 Index fell by 0.37%, the Dow Jones Industrial Average decreased by 0.18%, and the Nasdaq 100 Index dropped by 0.77%, reflecting investor concerns over the ongoing conflict in Iran and a general decline in market sentiment.
  • Oil Price Fluctuations: WTI crude oil prices surged over 4%, reaching elevated levels due to Iran's missile and drone strikes on Israel and US bases, raising fears about energy supply disruptions that could impact global economic recovery.
  • Economic Data: Despite market pressures, Q4 nonfarm productivity remained at 1.8%, while unit labor costs were revised up to 4.4%, exceeding expectations, indicating resilience in the economic fundamentals that may provide some support to the stock market.
  • International Tensions: Reports of Saudi Arabia and the UAE aligning with the Iran conflict have heightened market anxiety, as investors are closely monitoring the potential for increased US military deployment, which could escalate tensions and affect global market stability.
NASDAQ.COM
4.5
03-24NASDAQ.COM
US Stocks Decline Amid Ongoing Iran Conflict
  • Market Movement: The S&P 500 Index is down 0.16%, while the Dow Jones Industrial Average is up 0.13%, and the Nasdaq 100 Index has decreased by 0.50%, reflecting investor concerns over the ongoing Iran conflict, which is dampening market sentiment.
  • Rising Energy Prices: WTI crude oil prices have surged over 4% due to Iran's missile strikes on Israel and US bases, which not only limits stock market declines but also raises inflation expectations, potentially influencing future monetary policy decisions.
  • Economic Data Performance: The US Q4 nonfarm productivity remained unchanged at 1.8%, while unit labor costs were revised up to 4.4% from 2.8%, exceeding market expectations, indicating economic resilience that may support the stock market.
  • International Tensions Impact: Saudi Arabia and the UAE have taken steps toward joining the Iran war, potentially escalating the conflict, which increases market concerns about future geopolitical risks and drives investors towards safer assets.
NASDAQ.COM
4.5
03-24NASDAQ.COM
US Stocks Decline Amid Ongoing Iran Conflict
  • Market Decline: The S&P 500 Index fell by 0.80%, the Dow Jones Industrial Average by 0.83%, and the Nasdaq 100 by 0.98%, reflecting investor concerns over the ongoing Iran conflict, which may dampen market sentiment and affect short-term investment decisions.
  • Rising Oil Prices: WTI crude oil prices surged over 4% due to Iran's missile strikes on Israel and US bases, exacerbating global supply chain tensions and potentially raising inflation expectations in the coming months, which could influence the Fed's monetary policy.
  • Mixed Economic Data: Q4 nonfarm productivity remained unchanged at 1.8%, but unit labor costs were revised up to 4.4% from 2.8%, exceeding market expectations, indicating rising labor costs that may pressure corporate profits and subsequently impact stock market performance.
  • International Tensions: Saudi Arabia and the UAE have taken steps toward joining the Iran war, potentially escalating the conflict, and the high uncertainty surrounding future developments will continue to affect investor confidence and market volatility.
PRnewswire
1.0
03-11PRnewswire
Solventum to Participate in KeyBanc Healthcare Forum
  • Virtual Event Participation: Solventum's management will engage in a virtual fireside chat at the KeyBanc Healthcare Forum on March 18, 2026, starting at approximately 10:30 a.m. EDT, aimed at sharing the company's strategic vision and future outlook with investors.
  • Webcast Access: The event will feature a live webcast and replay, with details available on Solventum's investor website, enhancing interaction and transparency between the company and its investors.
  • Company Mission: Solventum is committed to delivering smarter, safer healthcare solutions through innovations at the intersection of health, materials, and data science, with the goal of improving patient lives and empowering healthcare professionals.
  • Industry Impact: As a new company with a legacy of breakthrough solutions, Solventum aims to lead innovation in the healthcare sector, driving industry advancement and addressing complex customer needs.
Wall Street analysts forecast SOLV stock price to rise
8 Analyst Rating
Wall Street analysts forecast SOLV stock price to rise
5 Buy
3 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
79.00
Averages
93.71
High
105.00
Current: 0.000
sliders
Low
79.00
Averages
93.71
High
105.00
Piper Sandler
Overweight
maintain
$98 -> $92
AI Analysis
2026-04-17
New
Reason
Piper Sandler
Price Target
$98 -> $92
AI Analysis
2026-04-17
New
maintain
Overweight
Reason
Piper Sandler lowered the firm's price target on Solventum to $92 from $98 and keeps an Overweight rating on the shares. The firm is making only minor changes to its model, including updates for currency movements and more appropriately reflecting GAAP restructuring charges in the P&L for 2026.
BTIG
Ryan Zimmerman
Buy
downgrade
$100 -> $89
2026-04-13
Reason
BTIG
Ryan Zimmerman
Price Target
$100 -> $89
2026-04-13
downgrade
Buy
Reason
BTIG analyst Ryan Zimmerman lowered the firm's price target on Solventum to $89 from $100 and keeps a Buy rating on the shares as part of a broader research name on Medical Technology. The firm is updating its models to reflect the CMS having announced its proposed rule for the FY27 inpatient prospective payment system which includes, among other things, preliminary commentary and decisions regarding new technology add-on payments, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for SOLV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Solventum Corp (SOLV.N) is 10.87, compared to its 5-year average forward P/E of 12.38. For a more detailed relative valuation and DCF analysis to assess Solventum Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
12.38
Current PE
10.87
Overvalued PE
13.67
Undervalued PE
11.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
9.04
Current EV/EBITDA
14.92
Overvalued EV/EBITDA
10.70
Undervalued EV/EBITDA
7.39

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.47
Current PS
1.42
Overvalued PS
1.64
Undervalued PS
1.31

Financials

AI Analysis
Annual
Quarterly

Whales Holding SOLV

M
Madison Avenue Partners, LP
Holding
SOLV
+18.65%
3M Return
G
General American Investors Company, Inc.
Holding
SOLV
+7.28%
3M Return
S
Scout Investments, Inc.
Holding
SOLV
+7.16%
3M Return
R
Ruffer LLP
Holding
SOLV
+6.69%
3M Return
A
Anchor Capital Advisors LLC
Holding
SOLV
+4.67%
3M Return
D
Diamond Hill Capital Management, Inc.
Holding
SOLV
+4.36%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Solventum Corp (SOLV) stock price today?

The current price of SOLV is 70.04 USD — it has decreased -0.62

What is Solventum Corp (SOLV)'s business?

Solventum Corporation is a global healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer needs. The Company’s segments include MedSurg, Dental Solutions, and Health Information System. MedSurg is a provider of solutions including negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies Original Equipment Manufacturer (OEM). Dental Solutions is a provider of a comprehensive suite of dental and orthodontic products including brackets, aligners, and restorative cement. Health Information Systems provides healthcare systems with software solutions, including computer-assisted physician documentation, and direct-to-bill and coding automation.

What is the price predicton of SOLV Stock?

Wall Street analysts forecast SOLV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SOLV is93.71 USD with a low forecast of 79.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Solventum Corp (SOLV)'s revenue for the last quarter?

Solventum Corp revenue for the last quarter amounts to 2.00B USD, decreased -3.71

What is Solventum Corp (SOLV)'s earnings per share (EPS) for the last quarter?

Solventum Corp. EPS for the last quarter amounts to 0.36 USD, increased 100.00

How many employees does Solventum Corp (SOLV). have?

Solventum Corp (SOLV) has 20000 emplpoyees as of April 21 2026.

What is Solventum Corp (SOLV) market cap?

Today SOLV has the market capitalization of 12.15B USD.